EQT

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Founded in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies with strong growth potential in various sectors, including healthcare, technology, and industrials. EQT employs a responsible ownership approach and aims to create sustainable value through active management and strategic guidance. The firm's investment strategies include private capital, real assets, credit, and public value, targeting companies with consistent cash flows and meaningful intrinsic value. EQT is also known for its expertise in the life sciences sector, having transitioned its healthcare investment arm into EQT Life Sciences, which focuses on innovative healthcare companies. The firm typically invests between €50 million and €600 million, with a preference for controlling or co-controlling stakes in its portfolio companies, which it holds for an average of four to eight years.

Sofia Ahuja

Partner

CHRISTIAN SHIN HØEGH ANDERSEN

Managing Director, Private Equity and Investment Advisory Professional

James Arrol

Managing Director, Fund Management

Teruyuki Asaoka

Managing Director

Andreas Aschenbrenner

Partner

Fouad Azzam

Partner

Fredrik Backman

Managing Director, Client Relations

Peter Balslev

Managing Director

Johann-Christoph Balzer

Partner, EQT Value-Add Infrastructure

Michael Bauer

Partner, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Eirik Benzon

Managing Director, BPEA EQT Team

William Bergström

Director

Lennart Blecher

Deputy Managing Partner

Clemens Van Blitterswijk

Founder of LSP Health Economics Fund

Mark Braganza

Partner, Investment Advisory

Marcus Brennecke

Institutional Partner, Marcus is a member of the Equity Partners Investment Committee and the Portfolio Performance Review Committee

Marc Brown

Partner and Head of EQT Growth

Nicolas Brugère

Partner and Head of France

Anna Brundtland

Managing Director

Philipp Bräuer

Associate

Drew Burdon

Partner

Caspar Callerstrom

Deputy CEO

Brian Chang

Partner

Kenneth Cheong

Partner

Henry Connon

Associate, Private Equity and Investment Advisory Professional

Crosby Cook

Partner, Infrastructure and Investment Advisory Professional

Guy Cui

Partner

Nicholas Curwen

Managing Director

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Johan Dettel

Partner

Mads Ditlevsen

Partner and Head of EQT Partners Denmark

Asís Echániz

Partner and Head of Spain

Andreas Eichelberger

Director

Frederik Elwing

Managing Director

Leeann Emmi

Vice President

Victor Englesson

Partner, Head of Private Equity Nordic and Co-Head of Global Technology Sector

Ali Farahani

Partner

Frank Feng

Managing Director

Michael Focking

Senior Partner

Mark Fogle

Partner and Head of EQT Exeter APAC

David Forde

Partner

Per Franzén

Head of Private Capital and Deputy Managing Partner

Juho Frilander

Managing Director

Joseph Fuda

Partner, Client Relations and Capital Raising

Florian Funk

Partner, Private Equity

Maria Gaffron

Associate, Infrastructure

Guillermo Garcia-Barrero

Managing Director

Carlos Garcia-Fuster

Partner, Private Equity

Henrik Giver

Managing Director

Simon Gold

Managing Director, Client Relations and Capital Raising

Wolfgang Gorny

Partner, Private Equity

Alexander Greenbaum

Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional

Fabian Grone

Partner, Infrastructure

Albert Gustafsson

COO of Private Capital Europe and North America

Floris van Halder

Managing Director

Sean Ham

Partner and Head of Asia Pacific

Kevin Hammon

Associate

Takanobu Hara

Partner

Jerry He

Partner and Head of China, Mid Market Asia Advisory Team

Frank Heckes

Partner, Private Equity

Erika Henriksson

Partner, Private Equity

Jak Hestnes

Managing Director and Board Member

Gerran Ho

Managing Director, Mid Market Asia

Christian Horn

Managing Director

Andreas Huber

Partner

Sara Huda

Managing Director and Head of Investment Services

Johan Daniel Hylander

Managing Director

Bert Janssens

Head of Private Equity Europe and Global Co-Head of Services, Private Capital

Patrick Jaslowitzer

Managing Director

Neha Jatar

Managing Director

Bjorn Jensen

Partner

Yan Jiao

Partner

Hakan Johansson

Senior Partner

Herman Johre

Associate

Maarten de Jong

Partner, EQT Private Equity

Nathalie Kaeser

Vice President, Private Equity

Kosmo Kalliarekos

Partner

Viviana Kane

Managing Director

Masahiko Kato

Managing Director and Head of Infrastructure Japan

Matthew Kestenbaum

Managing Director

Nils Ketter

Partner

Paul Kim

Managing Director

Jörg Kinberger

Partner, Private Equity

Cillian King

Managing Director

Martijn Kleijwegt

Managing Partner

Thomas Klews

Director

John de Koning

General Partner

Kees Koolen

Partner

Vesa Koskinen

Partner, Private Equity and Head of Finland

Gleb Kozyritskiy

Managing Director

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Elias Nissilä Källström

Managing Director

Ulrich Kollensperger

Partner

Tobias Küng

Managing Director, Infrastructure

Priscilla Lam

Managing Director, Portfolio Monitoring

Lance Lan

Managing Director, Exit Management

Adam Larsson

Managing Director

Robert Latz

Managing Director

Kenneth Lau

Associate

Edward Lavish

Managing Director, Portfolio Risk and Transactions

Juliette Lee

Associate

Eu Han Lee

Partner, Debt Capital Markets

Alex Lee

Partner

Hong Yong Leong

Partner

Janice Leow

Partner

William Liang

Director of European Firm

Benjamin Lim

Director

William Lindström

Managing Director

Gebhard Littich

Managing Director

Madeleine Magnerius

Director

Paola Maleh

Partner and Head of EMEA

Francesco Malvezzi

Managing Director, Infrastructure

Tadashi Maruoka

Partner

Axel Masucci

Managing Director

Arnav Mitra

Director

Martin Mix

Managing Director

Mikael Moll

Managing Director, Public Value

Jens Moritz

Partner

Maximilian Moser

Associate

Tomasz Muszynski

Director, Private Equity

Petri Myllyneva

Partner

Pascal Noel

Managing Director

Tetsuro Onitsuka

Partner and Head of Private Equity Japan

Alex Paganini

Associate, Infrastructure

Isabel de Paoli

Partner, Healthcare

Sydney Pardey

Managing Director

Tyler Parker

Managing Director

Daniel Perez

Partner

Christopher J. Popp

Managing Director

Anne Portwich

Partner

Shane Predeek

Partner

Federico Quitadamo

Partner and Head of Italy

Vai Rajan

Head of EMEA Private Wealth Capital Raising and Director - Client Relations and Capital Raising

Thomas Rajzbaum

Managing Director and Partner, EQT Infrastructure

Hermann Rauch

Managing Director

Vera Rebanova

Partner, Client Relations and Capital Raising

Johannes Reichel

Partner

Carl Renström

Partner

Matthias Riefer

Managing Director, Private Equity

Niklas Ringby

Partner and Co-Head of Public Value Advisory Team

Patrick Rodden

Managing Director and Head of Infrastructure for Australia and New Zealand

Maxwell Roitstein

Associate

Joachim Rothe

General Partner

Isidoor Rutten

Partner

Rob Ryan

Managing Director, Market Risk

Rosa Sammon, Darlene De La

Partner and Co-Head, Client Relations and Capital Raising

Carlos Santana

Partner

Anthony Santospirito

Partner

Mika Saukkonen

Managing Director, Infrastructure

Matthew Scattarella

Partner

Philip Scheltens

Managing Partner, Dementia Fund

Paul Schrotti

Partner

Nirav Shah

Partner, EQT Value-Add Infrastructure

Hemant Sharma

Managing Director

Gordon Shaw

Partner

Christian Sinding

CEO and Managing Partner

Piyush Singhvi

Managing Director, Infrastructure

Carl Sjölund

Partner, Infrastructure

Jared Small

Managing Director

Georg Stadler

Partner, Infrastructure

Dominik Stein

Partner and Head of EQT Growth Advisory Team

Joshua Stone

Managing Director, FO Head of Strategic Initiatives

Alexander Strassburger

Managing Director

Marc-Alexander Straubinger

Managing Director

Jan Stypulkowski

Managing Director

Sang Jun Suh

Partner

Anna Sundell

Partner, Infrastructure

Miriam Tawil

Partner and Investment Advisory Professional

Michiel Thiessen

Managing Director

Elly Thio

Managing Director

Erwin A. Thompson

Partner, Infrastructure

Matteo Thun

Partner

Andrew Tirbeni

Managing Director, EQT Client Relations and Capital Raising

Wei Jian Tor

Managing Director

Juan Vargas

Partner

Felice Verduyn

Investment Manager

Jan Vesely

Partner

Marcus Wallinder

Partner and Deputy Head of Client Relations and Capital Raising

Forrest Wang

Managing Director, Private Equity

Ethan Waxman

Partner

Mark Wegter

Managing Partner

Arno de Wilde

Investor

Rickard Wilson

Managing Director

Matthias Wittkowski

Partner

Ken Wong

Partner and Head of Asia Pacific, Infrastructure

Philipp R. Wörner

Director, Private Equity

Dayea Yeon

Managing Director and Head of Private Capital Korea

Shuting You

Managing Director

James Yu

Partner and Senior Bank Relationship Manager

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

Managing Director, Infrastructure

Stephan Leithner Ph.D

Partner

René Kuijten Ph.D

Managing Partner

Past deals in Netherlands

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Storytel

Post in 2021
Storytel AB is a prominent provider of streaming services for audiobooks and e-books, operating under the brands Storytel and Mofibo. Founded in 2005 and headquartered in Stockholm, Sweden, the company has established a significant presence in various countries, including Denmark, Norway, Finland, the Netherlands, and Poland, among others. Storytel's business is divided into two main segments: Streaming and Publishing. The Streaming segment offers subscription-based access to a vast library of digital content, while the Publishing segment includes several well-known imprints such as Norstedts and Massolit, as well as children's and young adult literature through B. Wahlström and Rabén & Sjögren. Additionally, Storytel has expanded its offerings to include digital subscriptions for newspapers and magazines, enhancing its portfolio in the publishing sector.

Mollie

Series C in 2021
Mollie B.V. is a payments platform that specializes in online payment processing for merchants. Founded in 2004 and headquartered in Amsterdam, the Netherlands, Mollie serves over 50,000 clients by providing an easy-to-implement solution for integrating various payment methods into websites and applications. The platform supports a wide range of local payment options, including Mastercard, VISA, PayPal, iDEAL, and Bitcoin, among others. Mollie focuses on simplifying the payment process for merchants, eliminating complexities associated with multiple payment methods through a powerful and user-friendly API. The company emphasizes technology, innovation, and reliability in its services.

Onward

Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Vico Therapeutics

Series A in 2020
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

VarmX

Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

Kiadis Pharma

Post in 2020
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Pharvaris

Series B in 2019
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

AM-Pharma

Series F in 2019
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Veritas Petroleum Services

Debt Financing in 2018
Veritas Petroleum Services (Asia) Pte Ltd. is a company specializing in testing, inspection, and advisory solutions tailored for the maritime industry. Founded in 1981 and based in Singapore, the company operates five laboratories in key global locations, including Rotterdam, Houston, and Fujairah. Veritas Petroleum Services assists ship operators, owners, and charterers in enhancing fuel management and operational efficiency while ensuring compliance with marine fuel regulations. Its services include fuel quality testing, fuel system checks, troubleshooting analysis, drinking water analysis, and bunker quantity surveys. Additionally, the company provides sampling equipment to help clients collect representative samples of delivered bunker fuels. Formerly known as DNV Petroleum Services Pte Ltd., the company rebranded in July 2014 and has expanded its customer service presence to multiple cities worldwide, including New Jersey, Tokyo, and London.

Dunlop Protective Footwear

Acquisition in 2018
Dunlop Protective Footwear is the leading global manufacturer of protective wellington boots. In more than 50 countries worldwide, the Company provides comfortable and protective footwear to the workers in Agriculture & Fishery, Food processing, Industry and the Oil, Gas & Mining industry. Dunlop has more than 500 employees, three production sites in the Netherlands, Portugal and the US, and sales people around the world. Dunlop Protective Footwear is headquartered in Raalte, the Netherlands.

Merus

Post in 2018
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Caiway

Acquisition in 2017
Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband, television, and telephony services. The company operates broadband connections to over 350,000 households and businesses, focusing on both urban and remote areas. In recent years, Caiway has expanded its fiber networks to enhance connectivity in municipalities and homes, establishing itself as a strong regional internet service provider. Key regions within Caiway's service area include Westland, Schiedam, and Almelo. By leveraging advanced cable and fiber infrastructure, Caiway aims to deliver reliable networking and high-quality services to its customers.

Xeltis

Series C in 2017
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Dentconnect

Acquisition in 2017
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

DELTA NV

Acquisition in 2016
Delta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands.

TransIP

Private Equity Round in 2016
TransIP Group B.V. is a Netherlands-based company that specializes in virtual private servers, domain name registration, and web hosting services. Founded in 2003, it primarily serves tech-savvy customers and information technology professionals in the Benelux region. TransIP offers a range of products, including BladeVPS PureSSD Pro, a self-managed tool equipped with web control panels and operating systems, as well as STACK, an online storage solution for file management. The company also provides SSL certificates to secure website connections, along with additional services such as forwarding, large storage options, and private networks. As of May 2019, TransIP operates as a subsidiary of Combell nv.

Mint Solutions

Series B in 2016
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Onward

Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

ViCentra

Series B in 2016
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Pharvaris

Series A in 2016
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis

Series B in 2015
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Merus

Series C in 2015
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Xeltis

Series B in 2014
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Bureau van Dijk

Acquisition in 2014
Bureau van Dijk Electronic Publishing BV specializes in providing comprehensive business information solutions, focusing on both public and private companies. Founded in 1991 and headquartered in Amsterdam, the company aggregates, cleans, and analyzes data on corporate structures and financials, offering insights for various sectors including finance, corporate, and public domains. Its extensive portfolio includes tools for transfer pricing, corporate valuation, credit analysis, compliance, and procurement, as well as databases containing economic indicators and forecasts. Bureau van Dijk also supports clients with tools for mergers and acquisitions, client onboarding, and market analysis, catering to a diverse clientele that includes banks, insurance companies, and academic institutions. As a subsidiary of Moody's Analytics since 2017, Bureau van Dijk continues to enhance its offerings through collaborations with leading information providers, enabling clients to make informed decisions and operate efficiently in a complex business environment.

Mint Solutions

Series A in 2014
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Merus

Series B in 2013
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kiadis Pharma

Venture Round in 2012
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Prosensa

Venture Round in 2012
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

Atos Medical

Acquisition in 2011
Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Koole Terminals

Acquisition in 2011
Koole is an independent international storage and transport company specialising in vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals and minerals.

arGEN-X

Series A in 2010
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Kreatech Diagnostics

Series B in 2010
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

Merus

Series B in 2010
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kreatech Diagnostics

Venture Round in 2009
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

BMEYE

Series A in 2009
BMEYE B.V. is a Netherlands-based company focused on the research and development of non-invasive cardiovascular monitoring technologies. Established in 2005 and located in Amsterdam, BMEYE specializes in devices that measure blood pressure and cardiac output. Its product lineup includes the Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version of the same technology; and the Finometer, a stationary monitor that provides non-invasive brachial pressure measurements. Additionally, BMEYE offers BeatScope, a software tool for analyzing arterial pressure waveforms, and Modelflow, a method for computing aortic flow waveforms. The company also has various devices like Cardiopres and Oxyflow for specific applications in research and clinical settings. BMEYE's products are distributed through a network of distributors and have received approval for sale in the U.S. and Europe, particularly targeting markets such as cardiology and anesthesia.

Kiadis Pharma

Venture Round in 2007
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

Prosensa

Series A in 2007
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

BMEYE

Series A in 2006
BMEYE B.V. is a Netherlands-based company focused on the research and development of non-invasive cardiovascular monitoring technologies. Established in 2005 and located in Amsterdam, BMEYE specializes in devices that measure blood pressure and cardiac output. Its product lineup includes the Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version of the same technology; and the Finometer, a stationary monitor that provides non-invasive brachial pressure measurements. Additionally, BMEYE offers BeatScope, a software tool for analyzing arterial pressure waveforms, and Modelflow, a method for computing aortic flow waveforms. The company also has various devices like Cardiopres and Oxyflow for specific applications in research and clinical settings. BMEYE's products are distributed through a network of distributors and have received approval for sale in the U.S. and Europe, particularly targeting markets such as cardiology and anesthesia.

DNage

Series A in 2005
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

OctoPlus

Series B in 2005
OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.

PamGene

Series B in 2003
PamGene International B.V. is a biomarker company based in s-Hertogenbosch, the Netherlands, specializing in a proprietary array-based platform that measures the activities of kinases and nuclear receptors. This technology supports a variety of applications, including lead identification and optimization, pre-clinical translational research, and biomarker development, particularly in oncology and medicine. Key products include the PamStation, an automated instrument for processing microarrays, and the PamChip, which is utilized on the PamStation to analyze various kinases and receptors. The BioNavigator software facilitates data interpretation and visualization. Additionally, PamGene provides training, consulting services, and a suite of online resources through Pamcloud, which encompasses an encyclopedia, a comprehensive database, and training materials related to kinases and nuclear receptors. Founded in 1999, PamGene operates as a subsidiary of Vitromics Healthcare Holding B.V.

PamGene

Series A in 2000
PamGene International B.V. is a biomarker company based in s-Hertogenbosch, the Netherlands, specializing in a proprietary array-based platform that measures the activities of kinases and nuclear receptors. This technology supports a variety of applications, including lead identification and optimization, pre-clinical translational research, and biomarker development, particularly in oncology and medicine. Key products include the PamStation, an automated instrument for processing microarrays, and the PamChip, which is utilized on the PamStation to analyze various kinases and receptors. The BioNavigator software facilitates data interpretation and visualization. Additionally, PamGene provides training, consulting services, and a suite of online resources through Pamcloud, which encompasses an encyclopedia, a comprehensive database, and training materials related to kinases and nuclear receptors. Founded in 1999, PamGene operates as a subsidiary of Vitromics Healthcare Holding B.V.

Haanpaa

Acquisition in 1999
Haanpaa is a logistics company specializing in the distribution of chemical products across Europe. Founded in 1949 by Jussi Haanpaa and headquartered in Vantaa, Finland, the company offers a range of services including storage, maintenance, transportation, and delivery in various European cities. Haanpaa also engages in sampling, monitoring, and packaging of chemical products, along with tank inspection and customer support services. The company produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, and agricultural commodities. With branches in Finland, Sweden, Norway, Estonia, Russia, and the Netherlands, Haanpaa has established a strong presence in the logistics sector for liquid chemical products. Since July 2016, it has operated as a subsidiary of Groupe Samat SA.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.